NDAORALTABLETPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TICLID (ticlopidine hydrochloride) by Roche is clinical pharmacology mechanism of action when taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. First approved in 1991.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TICLID (ticlopidine hydrochloride) is an oral antiplatelet agent that irreversibly inhibits ADP-induced platelet aggregation and fibrinogen binding. It is indicated for reducing thrombotic stroke risk in patients with cerebrovascular disease or a history of stroke. The drug works by interfering with platelet membrane function, producing platelet inhibition that persists for the platelet's lifetime.
LOE Approaching
Product is in late-stage lifecycle with reduced market demand and likely declining team investment as patent expiration approaches.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action When taken orally, ticlopidine hydrochloride causes a time- and dose-dependent inhibition of both platelet aggregation and release of platelet granule constituents, as well as a prolongation of bleeding time. The intact drug has no significant activity at…
Worked on TICLID at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.